—
C+
C+ The full Closelook — membership. Open the C+ overview

Bachem Holding AG (BANB.SW) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Bachem Holding AG

BANB.SW in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Bachem makes peptide-based active ingredients for drugmakers, covering both new peptide compounds and generic versions once patents expire. It also runs quality, regulatory and manufacturing services that let clients outsource production rather than build their own plants. The company is based in Bubendorf, Switzerland, and is majority owned by Ingro Finanz AG.
Where it sits in the stack
Bachem carries no seat in Rubin or Halo, our indices for the AI build-out and healthcare-innovation themes; it sits in the diary's broader Healthcare sector coverage as a peptide-manufacturing name rather than a stack constituent.
Who it is priced against
The diary's peer group draws on other scored Healthcare names, including argenx, Eli Lilly, Medpace, BeiGene and UCB; the market also names Novo Nordisk as a peptide-manufacturing comparison.
Why Closelook tracks it
Bachem carries a Closelook score with momentum as its strongest module and quality as its weakest; it holds no index seat and has drawn no diary quotes or mentions so far.
What the diary watches
Whether demand for peptide active ingredients, including generic versions as patents lapse, shifts the growth and quality readings that currently trail the rest of its score.

Bachem Holding AG (BANB.SW) trades on the SW exchange in Switzerland, classified under Healthcare.

The Closelook company score reads 50/100 composite (momentum 78, quality 41, valuation 34) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for BANB.SW, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Biotechnology · 8 names with week and year-to-date

Peer group

Biotechnology

Names in the same industry from the Closelook universe; scored names rank on their Closelook score, the rest on trend state.

Compared against BANB.SW on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return trailing yield 0.55%, annual · buybacks 3 m CHF in FY2025

Dividends and capital return

What BANB.SW pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 0.43 CHF per share · a 0.55% yield on the 2026-09-18 close 1 distribution, paid once a year 2026-09-18
  • Change on the year +2.6% against the prior twelve months prior twelve months 0.42 CHF per share
  • Last distribution 0.43 CHF per share as the price series records it, within days of the ex-date 2026-05-04
  • By calendar year 2025: 0.42 CHF (partial) · 2026: 0.43 CHF to date first distribution recorded in the three-year window: 2025-05-05
  • Dividends paid, FY2025 31 m CHF 34% of earnings
  • Buybacks, FY2025 3 m CHF 0.0% of today's market value
  • Share count −0.0% in FY2025 3 m CHF of stock-based compensation in the year
  • Capital returned 34 m CHF in a year of negative free cash flow dividends and buybacks together

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 50/100 · S&P 500 fund at 49, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-18
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 97th percentile of the window, +4.9% over 20 sessions. Factor regime → 2026-09-18
  • Sector × region Health care in Europe: +3.0% week · −4.5% month · −2.1% quarter · −5.0% yearThe Sector Engine cell this name lives in, from EXV4.XETRA; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-20
  • Sovereign pressure Index 0.07 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-18

FAQ · from the current data · as of 2026-09-19

Quick answers

What is Bachem Holding AG (BANB.SW)?

Bachem Holding AG trades as BANB.SW on the SW exchange (Switzerland) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-19.

Is BANB.SW in a Closelook index?

Not currently — Bachem Holding AG is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-19.

What is Bachem Holding AG's Closelook composite score?

50 out of 100, with momentum 78, quality 41 and valuation 34 sub-scores, as of 2026-09-19. Scores are Closelook's own research readings, not ratings or investment advice.

Where does BANB.SW trade against its moving averages?

Uptrend stack intact: Trades +4% vs the 50-day and +14.9% vs the 200-day average, 5.6% below the 52-week high and +62.9% off the 52-week low. Computed from daily closes. As of 2026-09-18 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Bachem Holding AG do?

Bachem makes peptide-based active ingredients for drugmakers, covering both new peptide compounds and generic versions once patents expire. It also runs quality, regulatory and manufacturing services that let clients outsource production rather than build their own plants. The company is based in Bubendorf, Switzerland, and is majority owned by Ingro Finanz AG. The diary's peer group draws on other scored Healthcare names, including argenx, Eli Lilly, Medpace, BeiGene and UCB; the market also names Novo Nordisk as a peptide-manufacturing comparison.

Where does Bachem Holding AG sit in the AI build-out?

Bachem carries no seat in Rubin or Halo, our indices for the AI build-out and healthcare-innovation themes; it sits in the diary's broader Healthcare sector coverage as a peptide-manufacturing name rather than a stack constituent. Bachem carries a Closelook score with momentum as its strongest module and quality as its weakest; it holds no index seat and has drawn no diary quotes or mentions so far.

Does Bachem Holding AG pay a dividend?

Bachem Holding AG has paid 0.43 CHF per share over the last twelve months, paid once a year, a trailing yield of 0.55% on the 2026-09-18 close; the last distribution recorded in the price series was 0.43 CHF on 2026-05-04. In fiscal 2025 the company paid 31 m CHF in dividends and bought back 3 m CHF of its own shares. The share count fell 0.0% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for BANB.SW, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.